Nishadil
Signup Signin
Delhi | 25°C (windy)
The RNA Gamble: Avidity Biosciences Faces Its Next Big Test

The RNA Gamble: Avidity Biosciences Faces Its Next Big Test
The Whisper Becomes a Roar: Why Novartis Needs Avidity’s RNA Revolution, Now More Than Ever

The Whisper Becomes a Roar: Why Novartis Needs Avidity’s RNA Revolution, Now More Than Ever
The Biotech Gambit: Novartis Reportedly Eyes Avidity in a High-Stakes Acquisition

The Biotech Gambit: Novartis Reportedly Eyes Avidity in a High-Stakes Acquisition
The Big Pharma Buzz: Why Novartis Might Be Eyeing Avidity's RNA Magic

The Big Pharma Buzz: Why Novartis Might Be Eyeing Avidity's RNA Magic
The Biotech Dance: Novartis Eyes Avidity in a Blockbuster Bid

The Biotech Dance: Novartis Eyes Avidity in a Blockbuster Bid
Game-Changing Merger: TransCode Therapeutics Acquires Polynoma, Secures $25M for Pancreatic Cancer Breakthrough

Game-Changing Merger: TransCode Therapeutics Acquires Polynoma, Secures $25M for Pancreatic Cancer Breakthrough
A New Era for Medicine: Quotient Sciences and CPI Unite to Propel RNA Therapeutics to Patients Faster

A New Era for Medicine: Quotient Sciences and CPI Unite to Propel RNA Therapeutics to Patients Faster
Load more..